Figure 4
From: OMN6 a novel bioengineered peptide for the treatment of multidrug resistant Gram negative bacteria
OMN6 demonstrates no cytotoxicity or hemolytic effect on mammalian cells. (A) Cytotoxicity assay via HEK293T cells in vitro. HEK293T cells were exposed to increasing concentrations of OMN6, while the control group was treated with double distilled water (DDW). Positive control groups were exposed to 10% DMSO or 21 µM melittin, that caused > 90% cytotoxicity. After 24 h, all experiment groups were subjected to Methylene-Blue assay in order to evaluate cell survival in comparison to the control group at 100%. (NS not significant; ****p < 0.0001). (B) Hemolysis assay via mouse red blood cells. Suspensions of 10% mouse erythrocytes were exposed to increasing concentrations of OMN6. The positive control group was treated with 1% Tween. The negative control group for the peptide treatment and for the Tween treatment were respectively treated with 0.9% saline solution and with PBS × 1. After a one-hour incubation, the relative amount of free hemoglobin (Hgb) was assessed as an indication of erythrocyte hemolysis (NS not significant; ****p < 0.0001).
